Human trophoblastic β1-glycoprotein as a differentiation factor of minor regulatory T-lymphocyte subsets (Treg, Th17). The involvement of CD9

Abstract

Human trophoblastic β1-glycoprotein (PSG) was studied in vitro as a differentiation factor of T-regulatory lymphocytes (Treg) and IL-17-producing lymphocytes. The role of CD9 molecules in realization of PSG effects was evaluated using anti-CD9 monoclonal antibodies. A human heterogeneous PSG was produced according to the original authors’ technique. It was revealed that PSG (10 or 100 μg/mL) increased the number of Treg (CD4+FOXP3+) and promoted the expression of CTLA-4 and GITR in these cells. It was found that PSG (10 and 100 μg/mL) impeded differentiation of the CD4+ cells into Th-17 lymphocytes (ROR-γt+IL-17A+). Some of the effects exerted by PSG (100 μg/mL) on the Treg/Th-17 differentiation was abolished upon the blockade of CD9 by antibodies; this concerned, in particular, the expression of FOXP3, CTLA-4, GITR, and ROR-γt. However, the depressing effects of PSG (100 μg/mL) on the expression and production of IL-17A did not depend on CD9. Thus, PSG favors the differentiation of CD4+ cells into Treg and suppresses the induction of Th17; some of the effects require the involvement of CD9.